Clinical AI company Aidoc said today it has closed a $150 million Series E led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Investment Advisors and NVIDIA's venture arm NVentures. The deal lifts Aidoc's total funding past $500 million and arrives less than a year after its prior growth round, signaling that vertical AI in regulated healthcare is one of the few corners of the market where late-stage capital is still flowing aggressively.
According to a report by Axios, Aidoc is now openly eyeing an IPO, joining a growing pipeline of AI-native enterprise companies positioning for public markets in 2026.
A foundation model built for the hospital, not the chatbot
At the center of the round is CARE, Aidoc's proprietary clinical foundation model. Earlier this year CARE received what the company describes as a landmark FDA clearance for a foundation model-based triage system across clinical imaging — a meaningful regulatory milestone given how cautious the agency has historically been about generalist medical AI.
CARE is delivered through Aidoc's aiOS platform, the company's enterprise operating layer for managing and governing AI inside hospitals. Aidoc says aiOS is now deployed across nearly 2,000 hospitals worldwide and analyzes more than 60 million patient cases per year, with cumulative analysis topping 110 million cases since launch.
That scale is what investors appear to be paying for. Unlike horizontal AI labs chasing general capability, Aidoc has spent years embedding inside radiology and emergency workflows, a defensible position that is hard to replicate from a foundation-model API alone.
What the new capital pays for
Aidoc said the funding will go toward three priorities: expanding CARE into additional clinical indications, building automated imaging draft report creation to support end-to-end radiology workflows, and accelerating global deployment of aiOS.
CEO and co-founder Elad Walach framed the bet in unusually long-horizon terms for a startup announcement. "By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error," Walach said.
Why this round matters
The Aidoc raise lands on a day dominated by Big Tech AI capex headlines — Meta lifting 2026 capital spending guidance, Microsoft defending Azure's AI run rate, and renewed scrutiny of OpenAI's revenue trajectory. Against that backdrop, a $150 million check into a clinical AI vendor with FDA-cleared infrastructure and 2,000 hospital customers is a quiet but pointed counter-signal.
It suggests that as horizontal model economics get harder to underwrite, capital is rotating toward AI companies that own a regulatory moat, a workflow integration, and recurring enterprise contracts — exactly the kind of profile public-market investors will demand if Aidoc does file. NVIDIA's participation through NVentures also fits the chipmaker's broader pattern of taking strategic stakes in physical and clinical AI, where its hardware roadmap meets long-tenured enterprise buyers.
If Aidoc ultimately reaches the public markets, it will be one of the first true tests of whether vertical, FDA-cleared clinical AI can command the same valuation premiums Wall Street has been extending to the frontier-model labs.
